AbbVie Ban on Botox Rival Seen as Setback for Evolus, Daewoong

A 21-month U.S. ban on imports of Jeuveau wrinkle treatment is “a major setback” for Evolus Inc. and its partner Daewoong Pharmaceutical Co. in their bid to compete with AbbVie Inc.’s Botox, though …
( read original story …)

---